Profile data is unavailable for this security.
About the company
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-8.54m
- Incorporated2004
- Employees12.00
- LocationKiora Pharmaceuticals Inc169 SAXONY RD., SUITE 212ENCINITAS 92024United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://kiorapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mustang Bio Inc | 0.00 | -2.34m | 6.64m | 6.00 | -- | 0.6796 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 6.70m | 2.00 | -- | 0.1261 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.94m | 1.00 | -- | 0.2701 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Synlogic Inc | 0.00 | -3.23m | 7.28m | 1.00 | -- | 0.705 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Aclarion Inc | 67.48k | -7.39m | 7.39m | 6.00 | -- | 0.1207 | -- | 109.56 | -1,687.50 | -1,687.50 | 0.1948 | 21.46 | 0.0082 | -- | 2.76 | 11,246.67 | -89.50 | -- | -97.72 | -- | -7.85 | -- | -10,868.49 | -- | -- | -25,428.22 | 0.00 | -- | -39.36 | -- | -43.60 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -8.54m | 7.65m | 12.00 | -- | 0.3187 | -- | -- | -2.05 | -2.05 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -24.99 | -48.77 | -27.44 | -56.18 | -- | -- | -- | -276.73 | -- | -- | 0.00 | -- | -- | 42.93 | 127.56 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.75m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 7.86m | -- | -- | 0.5497 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.19m | 8.29m | 17.00 | -- | 2.23 | -- | -- | -1.35 | -1.35 | 0.00 | 1.74 | 0.00 | -- | -- | 0.00 | -82.86 | -103.16 | -99.57 | -123.95 | -- | -- | -- | -- | -- | -138.68 | 0.00 | -- | -- | -- | -16.46 | -- | -- | -- |
| BioVie Inc | 0.00 | -17.48m | 8.37m | 13.00 | -- | 0.4345 | -- | -- | -5.13 | -5.13 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -72.35 | -260.69 | -79.73 | -454.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.73 | -- | -- | -- |
| StimCell Enegetics Inc | 0.00 | -935.22k | 8.66m | 0.00 | -- | -- | -- | -- | -0.0461 | -0.0461 | 0.00 | -0.0738 | 0.00 | -- | -- | -- | -2,062.23 | -844.03 | -- | -- | -- | -- | -- | -18,037.46 | -- | -17.22 | -- | -- | -- | -- | -297.42 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Adar1 Capital Management LLCas of 30 Sep 2025 | 167.94k | 4.57% |
| Nantahala Capital Management LLCas of 30 Sep 2025 | 156.43k | 4.25% |
| Stonepine Capital Management LLCas of 30 Sep 2025 | 140.60k | 3.82% |
| Citadel Securities LLCas of 30 Sep 2025 | 44.57k | 1.21% |
| DRW Securities LLCas of 30 Sep 2025 | 36.87k | 1.00% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 19.86k | 0.54% |
| Geode Capital Management LLCas of 30 Sep 2025 | 18.85k | 0.51% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 13.03k | 0.35% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 12.40k | 0.34% |
| Two Sigma Investments LPas of 30 Sep 2025 | 11.98k | 0.33% |
